ArticleCancer cell2012
Three down and one to go: modeling medulloblastoma subgroups.
Article in Cancer cell, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- UAB30, A Novel Rexinoid Agonist, Decreases Stemness In Group 3 Medulloblastoma Human Cell Line Xenografts.Translational oncology · 2019Article
- UAB30, a novel RXR agonist, decreases tumorigenesis and leptomeningeal disease in group 3 medulloblastoma patient-derived xenografts.Journal of neuro-oncology · 2018Article
- Molecular and in vivo characterization of cancer-propagating cells derived from MYCN-dependent medulloblastoma.PloS one · 2015Article
- Signals that regulate the oncogenic fate of neural stem cells and progenitors.Experimental neurology · 2014Review
- Noninvasive detection of glutamate predicts survival in pediatric medulloblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Salinomycin Suppresses PDGFRβ, MYC, and Notch Signaling in Human Medulloblastoma.Austin journal of pharmacology and therapeutics · 2014Article
- Critical role of zinc finger protein 521 in the control of growth, clonogenicity and tumorigenic potential of medulloblastoma cells.Oncotarget · 2013Article
- Children's Oncology Group's 2013 blueprint for research: central nervous system tumors.Pediatric blood & cancer · 2013Review
- The role of chromatin remodeling in medulloblastoma.Brain pathology (Zurich, Switzerland) · 2013Review
- Medulloblastomics: the end of the beginning.Nature reviews. Cancer · 2012Review
- A statin-regulated microRNA represses human c-Myc expression and function.EMBO molecular medicine · 2012Article
- Molecular subgroups of medulloblastoma.Expert review of neurotherapeutics · 2012Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
In this issue of Cancer Cell, Pei et al. and Kawauchi et al. describe murine models of an aggressive medulloblastoma subtype driven by Myc. These tumors have a cellular origin, microscopic appearance, and molecular profile distinct from those of three other major subgroups. Thus, the models fill a significant clinical need.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.